FILSPARI
Sep 16, 2024
Travere’s FILSPARI Approval Sparks Rivalry in the IgA Nephropathy Space
A year after failing to meet a trial endpoint, Travere Therapeutics can now relax. On 05 September 2024, the FDA upgraded FILSPARI’s conditional approval for the kidney disease IgA nephropathy to full approval. FILSPARI’s complete approval broadens its use, permitting the small molecule blocker to help slow kidn...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
